Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Performance of the 2023 diagnostic criteria for MOGAD: real-world application in a Chinese multicenter cohort of pediatric and adult patients

Fig. 4

Venn diagram of patients with definite or possible/non-MOGAD by each diagnostic criteria. *Possible MOGAD with red flags, but unable to verify antibody status through additional CBA testing due to technical limitations (three cases with CSF-restricted MOG-IgG positivity, four MS cases with typical MRI features, four cases with MNOS, one case with ependymoma). Abbreviations: CBA, Cell-based assay; CSF, Cerebrospinal fluid; MOG-IgG, Myelin oligodendrocyte glycoprotein-immunoglobulin G; MOGAD, Myelin oligodendrocyte glycoprotein antibody-associated disease; MRI, Magnetic resonance imaging; MS, Multiple sclerosis; MNOS, Myelin oligodendrocyte glycoprotein antibody and N-methyl-d-aspartate receptor antibody overlapping syndrome; STM, Short-segment myelitis

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us